Compare STZ & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STZ | VTRS |
|---|---|---|
| Founded | 1945 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Beverages (Production/Distribution) | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 21.0B |
| IPO Year | 1994 | 2019 |
| Metric | STZ | VTRS |
|---|---|---|
| Price | $135.44 | $18.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 12 |
| Target Price | ★ $150.87 | $19.90 |
| AVG Volume (30 Days) | 1.9M | ★ 8.0M |
| Earning Date | 10-06-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.97% | 2.67% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $9,139,000,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | N/A | $3.36 |
| Revenue Next Year | $1.47 | $2.40 |
| P/E Ratio | ★ $24.93 | $361.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $110.60 | $9.92 |
| 52 Week High | $168.60 | $18.75 |
| Indicator | STZ | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 67.42 | 57.21 |
| Support Level | $128.80 | $15.94 |
| Resistance Level | $139.30 | $18.41 |
| Average True Range (ATR) | 3.38 | 0.45 |
| MACD | 1.77 | 0.02 |
| Stochastic Oscillator | 83.00 | 73.38 |
Constellation Brands is the largest provider of alcoholic beverages across the beer, wine, and spirits categories in the US, generating more than 90% of revenue from Mexican beer imports under top-selling brands such as Modelo and Corona. The rest of the business includes some remaining wine and spirits brands, categories where the company has pruned assets in recent years. With its exclusive rights tied to the Mexican beer brands effective only in the US, the firm has limited revenue exposure to international markets. Constellation owns a 10% stake in Canopy Growth, a medicinal and recreational cannabis producer in Canada, and has a 50/50 joint venture with glass manufacturer Owens-Illinois in Mexico.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.